欢迎访问《中国临床药理学与治疗学》杂志官方网站,今天是 分享到:

中国临床药理学与治疗学 ›› 2024, Vol. 29 ›› Issue (3): 339-347.doi: 10.12092/j.issn.1009-2501.2024.03.013

• 综述与讲座 • 上一篇    下一篇

中医药减毒增效作用在免疫检查点治疗中的应用进展

张志鹏1,陈子琦2,田建辉1,3   

  1. 1上海中医药大学附属市中医医院肿瘤研究所,上海  200071;2上海中医药大学附属市中医医院实验中心,上海  200071;3上海中医药大学附属市中医医院肿瘤临床医学中心,上海  200071

  • 收稿日期:2023-09-20 修回日期:2023-12-12 出版日期:2024-03-26 发布日期:2024-02-29
  • 通讯作者: 田建辉,男,博士,主任医师,研究方向:中医药防治恶性肿瘤的临床与基础研究。 E-mail: tjhhawk@shutcm.edu.cn
  • 作者简介:张志鹏,男,博士,博士后,研究方向:中医药防治恶性肿瘤的基础研究。 E-mail: zhangzhipeng686@126.com
  • 基金资助:
    上海市炎癌转化病证生物学前沿研究基地(2021科技 03-12);上海市中医医院未来计划科技发展项目(WL-HBRC-2021001K);上海市卫生健康领军人才(2022LJ014);国家自然科学基金面上项目(81973517,82174245)

The attenuating and potentiating effects of traditional Chinese medicine in immune checkpoint therapy

ZHANG Zhipeng1, CHEN Ziqi2, TIAN Jianhui1,3   

  1. 1Oncology Research Center of Hospital of Traditional Chinese Medicine Affiliated to Shanghai University of Traditional Chinese Medicine, Shanghai 200071, China; 2Laboratory Center, Shanghai Municipal Hospital of Traditional Chinese Medicine, Shanghai University of Traditional Chinese Medicine, Shanghai 200071, China; 3Oncology Clinical Research Center of Hospital of Traditional Chinese Medicine Affiliated to Shanghai University of Traditional Chinese Medicine, Shanghai 200071, China
  • Received:2023-09-20 Revised:2023-12-12 Online:2024-03-26 Published:2024-02-29

摘要:

免疫治疗已成为癌症临床实践与科学研究中的全球瞩目焦点。近两年尤以Nivolumab、Pembrolizumab、Atezolizumab和Ipilimumab为代表的PD-1\PD-L1和CTLA-4抑制剂,针对免疫检查点在肿瘤免疫调节中的作用已在非小细胞肺癌、结肠癌、黑色素瘤和尿道癌等恶性肿瘤中取得了令人振奋的成果。中医药在中国有着悠久的历史,调控免疫检查点治疗恶性肿瘤具有一定优势,并且改善其不良事件也表现出较好的疗效。本文综述了中医药在调控免疫检查点和改善不良反应中的作用及其在免疫调节治疗中的应用前景。

关键词: 中医药, 恶性肿瘤, 免疫检查点, 免疫治疗, 不良反应

Abstract:

Immunotherapy has become a global focus in cancer clinical practice and scientific research.In the past two years, PD-1\PD-L1 and CTLA-4 inhibitors, especially Nivolumab, Pembrolizumab, Atezolizumab and Lpilimumab, have been used in non-small cell lung cancer, colon cancer. Promising results have been obtained in malignancies such as melanoma and urinary tract cancer. Traditional Chinese medicine has a long history in China. Modulating immune checkpoints has certain advantages in treating malignant tumors, and it has shown good efficacy in improving its adverse events. This article reviews the role of traditional Chinese medicine in regulating immune checkpoints and improving adverse reactions and its application prospects in immunomodulatory treatment.

Key words: traditional Chinese medicine, malignant tumours, immune checkpoint, immunotherapy, adverse reaction

中图分类号: